Author Archives: Ante

Edinburgh – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide preclinical results of OVX836 as part of a presentation entitled “OVX836 protects mice in lethal challenges with multiples strains of influenza A viruses”.

Beijing – PosterAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present preclinical results of OVX836 as part of a poster entitled “OVX836 a multimerized nucleoprotein based vaccine candidate protects mice against lethal challenges of multiple strains of influenza A viruses”.

Lausanne – Oral PresentationDr. Fergal Hill, Co-founder of Osivax, to provide preclinical results of OVX836 as part of a presentation entitled “OVX836, a multimerized nucleoprotein (NP) induces cellular responses against NP in various animal models challenges of multiple strains of influenza A viruses”.